Key facts
- This page summarizes Nathan L. Mata's Form 3 filing for BELITE BIO, INC (BLTE).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 14:45.
Nathan L. Mata - 18 Mar 2026 Form 3 Insider Report for BELITE BIO, INC (BLTE)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- BLTE
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 18 Mar 2026, 14:45:49 UTC
- Next SEC filing
- 02 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ NATHAN L. MATA
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nathan L. Mata filed Form 3 for BELITE BIO, INC (BLTE) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002013987
Primary reporting owner
MATA NATHAN L.
- Relationship
- Chief Scientific Officer
- Address
- 7708 MARKER ROAD, SAN DIEGO
- Signature
- /s/ NATHAN L. MATA
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLTE
holding
American depositary share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,666
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
BLTE
holding
Ordinary Share
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,666
- Date
- 18 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLTE
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 123,066
- Exercise price
- $6.00
- Footnotes
- F2
BLTE
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 100,000
- Exercise price
- $14.45
- Footnotes
- F3
BLTE
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 100,000
- Exercise price
- $48.46
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer.
Footnote F2
The option to purchase 123,066 ordinary shares had vested prior to March 18, 2026.
Footnote F3
The option shall vest (i) as to 50,000 ordinary shares on July 17, 2023, and (ii) as to 50,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following July 17, 2023, subject to continued service to the Issuer on each such date.
Footnote F4
The option shall vest as to 100,000 ordinary shares in 36 equal and continue monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on such date.
SEC remarks
Exhibit 24 - Power of Attorney